ArticleNeuro-oncology2016
Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
Open access · bronzeAbstract read
In one paragraph
Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Risk Factors for Survival in Patients With Medulloblastoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- SEOM clinical guideline for management of adult medulloblastoma (2020).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Guideline
- Real-world management and long-term outcomes in adolescent, young adult, and adult medulloblastoma: Experience from a monocentric series with multimodal and targeted approaches.Neuro-oncology practice · 2026Article
- Dual-task deep learning model for prediction of medulloblastoma molecular subgroups with preoperative brain MRI.La Radiologia medica · 2026Article
- Clinicopathological insights of supratentorial embryonal tumor with medulloblastoma-like histopathology in adulthood: A case report.Biomedical reports · 2025Article
- Multiparametric MRI-based machine learning system of molecular subgroups and prognosis in medulloblastoma.European radiology · 2025Article
- Immunohistochemical detection of 5-hydroxymethylcytosine as a prognostic biomarker in non-WNT/Non-SHH medulloblastomas.Scientific reports · 2025Article
- Advancing medulloblastoma therapy: strategies and survival insights.Clinical and experimental medicine · 2025Review
- Review
- Clinical and Molecular Characteristics and Outcome of Adult Medulloblastoma at a Tertiary Cancer Center.Cancers · 2024Article
- Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors.World journal of clinical oncology · 2023Review
- Research progress in molecular pathology markers in medulloblastoma.Exploration of targeted anti-tumor therapy · 2023Review
- Preoperative prediction of sonic hedgehog and group 4 molecular subtypes of pediatric medulloblastoma based on radiomics of multiparametric MRI combined with clinical parameters.Frontiers in neuroscience · 2023Article
- Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas.Acta neuropathologica · 2022Article
- Medulloblastoma in the Modern Era: Review of Contemporary Trials, Molecular Advances, and Updates in Management.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Adult medulloblastoma: a case report.Journal of medical case reports · 2022Article
- Review
- Radiomics signature for the prediction of progression-free survival and radiotherapeutic benefits in pediatric medulloblastoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022Article
- The use of Sonidegib in the adjuvant and advanced phases of Sonic Hedge Hog Mutant Medulloblastomas.Oxford medical case reports · 2022Article
- The Alliance AMBUSH Trial: Rationale and Design.Cancers · 2022Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 5 institutions in 4 countries.
Fu ZhaoNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Hiroko OhgakiNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Lei XuNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Felice GiangasperoNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Chunde LiNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Peng LiNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Zhijun YangNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Bo WangNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Xingchao WangNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Zhenmin WangNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Lin AiNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Jing ZhangNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Lin LuoNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Pinan LiuNeural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.); Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy (F.G.).
Beijing Tian Tan Hospital · CNCentre International de Recherche sur le Cancer · FRCapital Medical University · CNBeijing Institute of Neurosurgery · CNHarvard University · US
Funding
Dissecting Pediatric Brain Tumor Microenvironment to Improve TreatmentR35CA197743 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2015 to 2020
$5.7MNCI NIH HHS R35 CA197743World Health Organization 001
Abstract
backgroundRecent transcriptomic approaches have demonstrated that there are at least 4 distinct subgroups in medulloblastoma (MB); however, survival studies of molecular subgroups in adult MB have been inconclusive because of small sample sizes. The aim of this study is to investigate the molecular subgroups in adult MB and identify their clinical and prognostic implications in a large, single-institution cohort.
methodsWe determined gene expression profiles for 13 primary adult MBs. Bioinformatics tools were used to establish distinct molecular subgroups based on the most informative genes in the dataset. Immunohistochemistry with subgroup-specific antibodies was then used for validation within an independent cohort of 201 formalin-fixed MB tumors, in conjunction with a systematic analysis of clinical and histological characteristics.
resultsThree distinct molecular variants of adult MB were identified: the SHH, WNT, and group 4 subgroups. Validation of these subgroups in the 201-tumor cohort by immunohistochemistry identified significant differences in subgroup-specific demographics, histology, and metastatic status. The SHH subgroup accounted for the majority of the tumors (62%), followed by the group 4 subgroup (28%) and the WNT subgroup (10%). Group 4 tumors had significantly worse progression-free and overall survival compared with tumors of the other molecular subtypes.
conclusionsWe have identified 3 subgroups of adult MB, characterized by distinct expression profiles, clinical features, pathological features, and prognosis. Clinical variables incorporated with molecular subgroup are more significantly informative for predicting adult patient outcome.
Indexed as
AdolescentAdultbeta CateninBiomarkers, TumorCerebellar NeoplasmsDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHedgehog ProteinsHumansLongitudinal StudiesMaleMedulloblastomaMiddle AgedPrognosisbeta CateninBiomarkers, TumorCTNNB1 protein, humanHedgehog ProteinsWnt Proteinsadult medulloblastomahistologymolecular subgroupprognosissurvival
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.